SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe

SomaLogic’s 7,000-plex SomaScan® Platform will be used in proteomics testing at scale in Europe.

BOULDER, Colo. and L’AQUILA, Italy, July 24, 2023 /PRNewswire/ — SomaLogic Operating Co. Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with Dante Genomics, a global leader in genomics and precision medicine, to offer a comprehensive solution for proteomics testing at scale in Europe. Dante will be the first SomaLogic authorized site in Italy.

Dante Genomics

“Over the past seven years, Dante has been intensely focused on enhancing the clinical utility of the genome, and in partnering with SomaLogic, we will now work together to enhance the research and discovery capabilities of the proteome,” said Andrea Riposati, Co-founder and CEO of Dante Genomics. “By combining proteomics and genomics, we will develop clinical insights and actionable results. We are excited for the future of multiomics, where partnerships like this will mean overall better healthcare for more people around the world.”

Dante Genomics will run SomaLogic’s technology out of its laboratory in Italy, providing proteomics services for the European market. SomaLogic’s 7,000-plex SomaScan® Platform can be applied across research and discovery. It can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample.

SomaLogic and Dante Genomics will partner to offer one of the first multiomic capabilities to support clinical research discovery, expanding the databases and total addressable market for both companies.

Italy is a leader in life science research in Europe, showing promising growth in -omics research in academic and private sectors,” said SomaLogic Chief Executive Officer Adam Taich. “We’re excited to be supporting Dante Genomics’s vision for accelerating the clinical research of proteomics.”

For more than twenty years, SomaLogic has grown from its roots in the research lab to become a global leader in proteomics with technology that delivers the quality and quantity of biological insights life science researchers need – from lab to last mile.

About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and software. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

About SomaLogic
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at and follow @somalogic on LinkedIn.

Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.   Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Dante Genomics Contact
Laura D’Angelo
VP of Investor Relations
+39 0862 191 0671

SomaLogic Media Contact
Emilia Costales

SomaLogic Investor Contact
Marissa Bych
Gilmartin Group LLC


Logo –

Logo –

Cision View original content: